Mariamma Charles Thekkumpurath

“Repurposing Ketorolac for the treatment of Renal Cell Carcinoma” (Ghosalkar JD, Iyer SR, Raut SR, Thekkumpurath, Malhotra G and Joshi KS*) United states patents application publication Jan 2018 The present study describes the molecular mechanismsunderlining the synergistic inhibition of RCC growth byKetorolac. We thus conclude that the remarkable efficacycan be attributed to the dual mechanism of action ofKetorolac as a COX and HIF-1α inhibitor and Par-4 inducermaking it an interesting candidate for repurposing againstrenal cell carcinoma. The synergy observed in in vivo efficacystudy in absence of toxicity provides a rationale for the useof Ketorolac… Show more The present study describes the molecular mechanismsunderlining the synergistic inhibition of RCC growth byKetorolac. We thus conclude that the remarkable efficacycan be attributed to the dual mechanism of action ofKetorolac as a COX and HIF-1α inhibitor and Par-4 inducermaking it an interesting candidate for repurposing againstrenal cell carcinoma. The synergy observed in in vivo efficacystudy in absence of toxicity provides a rationale for the useof Ketorolac in combination with Sunitinib. Show less